These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26444701)

  • 21. Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study.
    Ng CG; Boks MP; Roes KC; Zainal NZ; Sulaiman AH; Tan SB; de Wit NJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):491-8. PubMed ID: 24503279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of valproic acid and amitriptyline: analysis of therapeutic drug monitoring data under naturalistic conditions.
    Unterecker S; Burger R; Hohage A; Deckert J; Pfuhlmann B
    J Clin Psychopharmacol; 2013 Aug; 33(4):561-4. PubMed ID: 23775047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study.
    Gabriel A
    Depress Anxiety; 2006; 23(8):485-8. PubMed ID: 16845646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.
    Citrome L; Gommoll CP; Tang X; Nunez R; Mathews M
    Int Clin Psychopharmacol; 2015 Mar; 30(2):75-81. PubMed ID: 25396353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
    Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
    Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study.
    Kautzky A; Dold M; Bartova L; Spies M; Kranz GS; Souery D; Montgomery S; Mendlewicz J; Zohar J; Fabbri C; Serretti A; Lanzenberger R; Dikeos D; Rujescu D; Kasper S
    Acta Psychiatr Scand; 2019 Jan; 139(1):78-88. PubMed ID: 30291625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
    Turkoz I; Nelson JC; Wilkinson ST; Borentain S; Macaluso M; Trivedi MH; Williamson D; Sheehan JJ; Salvadore G; Singh J; Daly E
    Psychiatry Res; 2023 May; 323():115165. PubMed ID: 37019044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study.
    Bares M; Novak T; Kopecek M; Stopkova P; Cermak J; Kozeny J; Höschl C
    Int J Psychiatry Clin Pract; 2013 Feb; 17(1):35-43. PubMed ID: 22486580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder.
    Kagawa S; Mihara K; Nakamura A; Nemoto K; Suzuki T; Nagai G; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):730-3. PubMed ID: 24819973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression.
    Targum SD; Daly E; Fedgchin M; Cooper K; Singh JB
    J Psychiatr Res; 2019 Apr; 111():68-73. PubMed ID: 30685564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
    Pangallo B; Dellva MA; D'Souza DN; Essink B; Russell J; Goldberger C
    J Psychiatr Res; 2011 Jun; 45(6):748-55. PubMed ID: 21511276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression.
    Turkoz I; Alphs L; Singh J; Jamieson C; Daly E; Shawi M; Sheehan JJ; Trivedi MH; Rush AJ
    Acta Psychiatr Scand; 2021 Mar; 143(3):253-263. PubMed ID: 33249552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
    Loebel A; Cucchiaro J; Silva R; Kroger H; Sarma K; Xu J; Calabrese JR
    Am J Psychiatry; 2014 Feb; 171(2):169-77. PubMed ID: 24170221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.